Vulvar Squamous Cell Carcinoma: Comprehensive Genomic Profiling of HPV+ Versus HPV- Forms Reveals Distinct Sets of Potentially Actionable Molecular Targets.
Journal
JCO precision oncology
ISSN: 2473-4284
Titre abrégé: JCO Precis Oncol
Pays: United States
ID NLM: 101705370
Informations de publication
Date de publication:
2020
2020
Historique:
accepted:
28
04
2020
entrez:
14
9
2020
pubmed:
15
9
2020
medline:
15
9
2020
Statut:
epublish
Résumé
Vulvar squamous cell carcinoma (vSCC) encompasses two predominant variants: one associated with detectable high-risk strains of human papillomavirus (hrHPV) and a second form often occurring in the context of chronic dermatitis in postmenopausal women. Genomic assessment of a large-scale cohort of patients with aggressive vSCC may identify distinct mutational signatures. Tumor samples from a total of 280 patients with vSCC underwent hybridization capture with analysis of up to 406 cancer-related genes. Human papillomavirus (HPV) sequences were detected by de novo assembly of nonhuman sequencing reads and aligned to the RefSeq database. Immunohistochemistry for programmed death-ligand 1 (PD-L1) was assessed. One hundred two of 280 vSCCs (36%) contained hrHPV sequences, predominantly HPV 16 (88%). The HPV-positive (HPV+) group was significantly younger (median age, 59 Comprehensive molecular profiles of vSCC vary considerably with hrHPV status and may inform patient selection into clinical trials. Sixty-one percent of HPV+ vSCCs had a pathogenic alteration in the PI3K/mTOR pathway, whereas HPV- vSCCs showed alterations in
Identifiants
pubmed: 32923875
doi: 10.1200/PO.19.00406
pii: 1900406
pmc: PMC7446361
pii:
doi:
Types de publication
Journal Article
Langues
eng
Informations de copyright
© 2020 by American Society of Clinical Oncology.
Déclaration de conflit d'intérêts
The following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated unless otherwise noted. Relationships are self-held unless noted. I = Immediate Family Member, Inst = My Institution. Relationships may not relate to the subject matter of this manuscript. For more information about ASCO's conflict of interest policy, please refer to www.asco.org/rwc or ascopubs.org/po/author-center. Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments). Erik A. WilliamsEmployment: Foundation Medicine Stock and Other Ownership Interests: F. Hoffmann-La RocheRadwa SharafEmployment: Foundation Medicine Stock and Other Ownership Interests: RocheMeagan MontesionStock and Other Ownership Interests: RocheEthan S. SokolEmployment: Foundation Medicine Stock and Other Ownership Interests: Roche (Parent of FMI)Dean C. PavlickStock and Other Ownership Interests: RocheMolly McLaughlin-DrubinEmployment: Foundation Medicine Employment: PatientsLikeMe (I), Precision for Medicine (I) Stock and Other Ownership Interests: Roche Travel, Accommodations, Expenses: Foundation MedicineRachel ErlichEmployment: Foundation Medicine Stock and Other Ownership Interests: Foundation MedicineKevin Jon WilliamsStock and Other Ownership Interests: Hygieia Stock and Other Ownership Interests: Gemphire Therapeutics Consulting or Advisory Role: Gemphire Therapeutics, Inc. Research Funding: Novo NordiskJeff M. VenstromEmployment: Genentech, Foundation Medicine Leadership: Genentech Stock and Other Ownership Interests: Genentech Research Funding: Genentech, Foundation Medicine Travel, Accommodations, Expenses: GenentechBrian M. AlexanderEmployment: Foundation Medicine Leadership: Foundation Medicine Stock and Other Ownership Interests: Roche Research Funding: Eli Lilly (Inst), Puma (Inst), Celgene (Inst) Open Payments Link: https://openpaymentsdata.cms.gov/physician/854258/summaryNikunj ShahEmployment: Foundation MedicineNatalie DanzigerEmployment: Foundation MedicineAmanda C. HemmerichEmployment: Foundation Medicine Stock and Other Ownership Interests: Foundation Medicine (Inst)Eric A. SeversonEmployment: Foundation Medicine, Partners Healthcare Stock and Other Ownership Interests: Foundation MedicineJonathan Keith KillianEmployment: Foundation Medicine Stock and Other Ownership Interests: Foundation MedicineDouglas I. LinEmployment: Foundation MedicineJeffrey S. RossEmployment: Foundation Medicine Leadership: Foundation Medicine Stock and Other Ownership Interests: Foundation Medicine Consulting or Advisory Role: Celsius Therapeutics Research Funding: Foundation MedicineJulie Y. TseEmployment: Foundation Medicine, Pathology Watch Travel, Accommodations, Expenses: Foundation MedicineShakti H. RamkissoonEmployment: Foundation Medicine Stock and Other Ownership Interests: Foundation MedicineJulia A. ElvinEmployment: Foundation Medicine No other potential conflicts of interest were reported.
Références
Gynecol Oncol. 2018 Sep;150(3):552-561
pubmed: 29980281
Adv Anat Pathol. 2017 Jul;24(4):201-214
pubmed: 28590952
Gynecol Oncol. 2008 Nov;111(2):289-97
pubmed: 18768215
JCI Insight. 2018 Jul 26;3(14):
pubmed: 30046007
N Engl J Med. 2003 Feb 6;348(6):518-27
pubmed: 12571259
Cell. 2019 Mar 7;176(6):1282-1294.e20
pubmed: 30849372
J Otolaryngol Head Neck Surg. 2016 Oct 28;45(1):54
pubmed: 27793210
Clinics (Sao Paulo). 2018 Sep 06;73(suppl 1):e539s
pubmed: 30208168
Int J Gynecol Pathol. 2006 Jan;25(1):22-9
pubmed: 16306780
Gynecol Oncol. 2016 Sep;142(3):427-34
pubmed: 27401841
Gynecol Oncol. 2013 Aug;130(2):269-74
pubmed: 23672928
Dermatology. 2014;228(2):145-51
pubmed: 24516059
Pathology. 2016 Jun;48(4):291-302
pubmed: 27113549
Cancer Med. 2018 Sep;7(9):4542-4553
pubmed: 30030907
Nat Biotechnol. 2013 Nov;31(11):1023-31
pubmed: 24142049
Int J Cancer. 2015 Jan 1;136(1):98-107
pubmed: 24817381
Cancer Discov. 2018 Jul;8(7):822-835
pubmed: 29773717
Genome Res. 2016 Feb;26(2):174-82
pubmed: 26755635
Cancer Lett. 2018 Sep 1;431:64-72
pubmed: 29807113
Oncol Lett. 2016 Nov;12(5):4107-4116
pubmed: 27895779
Histopathology. 2013 Jan;62(1):161-75
pubmed: 23190170
Gynecol Oncol. 2015 Jan;136(1):143-57
pubmed: 25448458
Oncol Lett. 2015 Aug;10(2):600-606
pubmed: 26622540
Clin Cancer Res. 2018 Mar 15;24(6):1287-1295
pubmed: 29298798
Nature. 2017 Mar 16;543(7645):378-384
pubmed: 28112728
Crit Rev Oncol Hematol. 2016 Oct;106:1-13
pubmed: 27637349
Genome Med. 2017 Apr 19;9(1):34
pubmed: 28420421
Mod Pathol. 2010 Mar;23(3):404-12
pubmed: 20062014
Viruses. 2017 Jul 10;9(7):
pubmed: 28698524
PLoS Comput Biol. 2018 Feb 7;14(2):e1005965
pubmed: 29415044
Oncogenesis. 2018 Aug 15;7(8):61
pubmed: 30108202
Clin Cancer Res. 2017 Aug 1;23(15):4501-4510
pubmed: 28377483
Gynecol Oncol. 2012 Mar;124(3):529-33
pubmed: 22079361
J Pathol. 2014 Dec;234(4):441-51
pubmed: 25043390
Oncogene. 2005 Apr 7;24(15):2585-8
pubmed: 15735736
Oncogene. 2018 Jul;37(29):3924-3936
pubmed: 29695832
Gynecol Oncol. 2017 Aug;146(2):305-313
pubmed: 28536037
Obstet Gynecol. 2006 May;107(5):1018-22
pubmed: 16648405
Int J Radiat Oncol Biol Phys. 1998 Aug 1;42(1):79-85
pubmed: 9747823
Clin Epigenetics. 2017 Sep 6;9:95
pubmed: 28878842
Nature. 2013 Aug 22;500(7463):415-21
pubmed: 23945592
Cell Rep. 2019 Mar 5;26(10):2651-2666.e6
pubmed: 30840888
Anticancer Res. 2005 May-Jun;25(3A):1739-45
pubmed: 16033093
Cancers Head Neck. 2018 Jun 4;3:3
pubmed: 31093356
Science. 2017 Mar 24;355(6331):1324-1330
pubmed: 28336670
Exp Mol Med. 2018 Feb 9;50(2):e442
pubmed: 29422544
Oncogene. 2018 Mar;37(10):1354-1368
pubmed: 29269867
Oncotarget. 2017 Aug 3;8(42):72564-72576
pubmed: 29069809
J Mol Diagn. 2018 Sep;20(5):686-702
pubmed: 29936259
Oncogene. 1994 Jun;9(6):1655-9
pubmed: 8183560
Hum Pathol. 2012 Sep;43(9):1386-93
pubmed: 22406359
Vaccine. 2012 Nov 20;30 Suppl 5:F12-23
pubmed: 23199955
Papillomavirus Res. 2018 Dec;6:46-51
pubmed: 30401640